Amirose London Holdings PLC

Earnings Release • Sep 30, 2025

National Storage Mechanism | Additional information

RNS Number : 2974B

Amirose London Holdings PLC

30 September 2025

The   information   contained within this announcement is deemed by the Company to constitute   inside   information   stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of   UK   domestic law by virtue of the   European Union   (Withdrawal) Act 2018.     Upon the publication of this announcement via the   Regulatory   Information   Service, this   inside   information   is now considered to be in the public domain.  

30 September 2025

AMIROSE LONDON HOLDINGS PLC

(''Amirose'' or the "Company'')

FINAL RESULTS FOR THE 16-MONTHS ENDING 31 MARCH 2025

Amirose London Holdings PLC is pleased to announce its results for the year ended 31 March 2025. The results relate to the activities of File Forge Technology PLC prior to its acquisition of Amirose London Limited in a reverse takeover transaction which completed on 6 June 2025 ("Transaction"). File Forge Technology PLC was renamed Amirose London Holdings PLC. Following completion of the Transaction, the Company's strategy and operations have fundamentally changed.

For further information, please contact:

Amirose London Holdings PLC   Michael Heath  Chief Executive Officer	+44 7391 407 210
Alfred Henry Corporate Finance ( Corporate Advisor)   Nick Michaels/Maya Klein Wassink	+44 (0) 20 8064 4056
Capital Plus Partners Limited (Broker)   Dominic Berger	+44 (0) 7799 888 544
Novum Securities Limited (Broker)   Jon Belliss/Colin Rowbury	+44 20 7399 9400

Chairman's Statement

Dear Shareholders,

I am delighted to present the results of Amirose London Holdings PLC (formerly File Forge Technology PLC and Clarify Pharma PLC) for the 16-month period ended 31 March 2025. This has been a defining chapter in the Company's journey,  marked by decisive change, a sharpened sense of purpose, and the laying of foundations for sustainable long-term growth.

Having originally pursued a strategy in the decentralised storage sector, the previous Board reached the view that this model did not offer the most effective pathway to shareholder value. After careful consideration, the previous Board concluded that greater potential lay in acquiring an established operating business with a proven revenue base, long-standing customer relationships, and genuine scalability.

In June 2025, the Company completed the reverse takeover of Amirose London Limited, a contract manufacturer with a distinguished track record in the personal care sector. For decades, Amirose has supplied some of the most recognised brands from its facility in Thetford, Norfolk, reaching local and global markets. Its reputation is built not only on product quality but also on reliability, flexibility, and the ability to adapt quickly to client needs. Alongside this transaction, the Company adopted a new name, Amirose London Holdings PLC.

The results for the reporting period demonstrate the impact of this new direction. The Company recorded a total comprehensive income of £24,000, a significant turnaround from the prior year's total comprehensive loss of £810,000. This reflects both disciplined cost management and the orderly disposal of non-core assets. More importantly, it validates our conviction that Amirose represents a platform with the ability to deliver both financial stability and growth.

Looking forward, the opportunity before us is compelling and exciting.  Amirose operates a high-margin, mid-volume production model, which positions us to serve a growing number of personal care brands that value agility, quality, and trust over sheer scale. With shifting consumer demand, supply chain realignment, and an increased emphasis on domestic and near-shore production, we see a market environment that plays directly to our strengths.

Equally transformative has been the strengthening of our Board. The reconstituted Board now brings not only deep governance and financial expertise, gained from service on numerous public company boards, but also invaluable operational experience from successful manufacturing businesses. In addition, the new Board has created a plethora of connections across the personal care industry and new avenues in the sector. These relationships are already opening doors and presenting new opportunities.

The geopolitical environment, while challenging, has also created a change in global supply chains, and we are well placed to capture business flows that might previously have gone elsewhere.

The untapped potential of this network, combined with our established reputation and facility, gives us confidence that the next stage of growth can be both meaningful and enduring. We will continue to invest in strengthening customer partnerships, upgrading our manufacturing capabilities, and building on the trust that Amirose has cultivated over decades.

On behalf of the new Board of Amirose London Holdings PLC, I wish to thank you, our shareholders, for your continued support and belief as we transition into this exciting new era.

Aleksandra Binkowska

Non-Executive Chairman

Date:  29 September 2025

Statement of Comprehensive Income for the 16-months period ending 31 March 2025

	16-month period ended 31 March	Year ended 30 November
2025 £'000	2023                   £'000
Continuing Operations
Revenue	-	-
Cost of sales	-	-
Gross profit	-	-
Administrative expenses	208	(735)
Capital loss on investments	(63)	-
Operating Profit / (Loss)	145	(735)
Fair value gains / (losses)	(148)	-
Finance costs	-	-
Profit / (Loss) before taxation	(3)	(735)
Taxation	-	-
Profit / (Loss) after taxation	(3)	(735)
Other comprehensive income	27	(75)
Total comprehensive income/(loss) for the year attributable to shareholders from continuing operations	24	(810)
Basic earnings per share - pence	0.008	(0.25)
Diluted earnings per share - pence	0.007	(0.25)

Statement of Financial position as at 31 March 2025

	As at 31 March 2025 £'000	As at 30 November 2023 £'000
NON-CURRENT ASSETS
Intangible assets	132	-
Investments	3	706
TOTAL NON-CURRENT ASSETS	135	706
CURRENT ASSETS
Cash and cash equivalents	3	167
Trade and other receivables	21	10
TOTAL CURRENT ASSETS	24	177
TOTAL ASSETS	159	883
EQUITY
Share capital	297	297
Share premium	2,810	2,810
Share based payment reserve	-	575
Retained earnings	(3,061)	(3,085)
TOTAL EQUITY	46	597
CURRENT LIABILITIES
Trade and other payables	113	286
Deferred revenue	-	-
Lease liability	-	-
TOTAL CURRENT LIABILITIES	113	286
TOTAL LIABILITIES	113	286
TOTAL EQUITY AND LIABILITIES	159	883

Cash Flow Statement for the 16-months period ending 31 March 2025

		16-month period ended 31 March	Year ended 30 November
2025	2023
		£'000	£'000
Cash flow from operating activities
Profit / (Loss) for the financial year		24	(810)
Adjustments for:
Write down / revaluation		523	163
Foreign exchange movements		(27)	75
Capital (gain) / loss		63	-
Services settled by issue of warrants		(575)	-
Changes in working capital:
Decrease / (Increase) in trade and other receivables		(11)	80
Increase / (decrease) in trade and other payables		(172)	224
Net cash used in operating activities		(175)	(268)
Cash flows from investing activities
Net Purchase of intangible assets		(279)	-
Investments - disposals		290	-
Net cash used in investing activities		11	-
Cash flows from financing activities
Proceeds from issue of shares		-	-
Net cash (used in)/generated from financing activities		-	-
Net (decrease)/increase in cash and cash equivalents		(164)	(268)
Cash and cash equivalents at beginning of the period		167	435
Cash and cash equivalents at end of the period		3	167

NOTES TO PRELIMINARY RESULTS FOR THE PERIOD ENDED 31 March 2025

1.    The financial information set out above does not constitute statutory accounts for the purpose of Section 434 of the Companies Act 2006. The financial information has been extracted from the statutory accounts of Amirose London Holdings PLC and is presented using the same accounting policies, which have not yet been filed with the Registrar of companies, but on which the auditors gave an unqualified report on 29 September 2025.

The preliminary announcement of the results for the year ended 31 March 2025 was approved by the board of directors on 29 September 2025.

2.         Earnings per Share

	31 Mar 2025	30 Nov 2023
Profit / (Loss) for the year from continuing operations - £'000	24	(810)
Weighted number of ordinary shares in issue (number)	297,196,000	297,196,000
Basic earnings per share from continuing operations - pence	0.008	(0.25)
Diluted earnings per share from continuing operations - pence	0.007	(0.25)

- ends -

The Directors accept responsibility for this announcement.

About Amirose London Holdings PLC    

Amirose provides contract manufacturing services in the personal care sector for global and boutique premium brands. Amirose will assist such brands in developing formulations for personal care products, sourcing packaging, bulk manufacturing, filling and distributing. Amirose also helps customers navigate the regulatory and compliance framework required to bring a product to market. Amirose has approximately 75 customers and services over 200 brands. Amirose's manufacturing facilities are in Thetford, Norfolk. Amirose currently has 86 employees.  

Amirose aims to transform its contract manufacturing business, which has so far generated modest profits while utilising only a portion of its factory's capacity, into a thriving enterprise by fully leveraging excess capacity, infrastructure, and the expertise of its team. Amirose expects to drive growth organically and through strategic acquisitions in the future.  

For more information on the Company please visit www.amiroselondon.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXEAXNNALKSEFA